Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study

Research output: Contribution to journalJournal articleResearchpeer-review

  • S A Peeters
  • L Engelen
  • J Buijs
  • A Jorsal
  • H-H Parving
  • L Tarnow
  • Rossing, Peter
  • C G Schalkwijk
  • C D A Stehouwer

BACKGROUND: Altered regulation of extracellular matrix remodeling by matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinase (TIMP) may contribute to vascular complications in type 1 diabetes. We investigated associations between plasma MMP-1, -2, -3, -9, -10 and TIMP-1, and cardiovascular events and all-cause mortality in type 1 diabetic patients.

METHODS: We prospectively followed 337 type 1 diabetic patients [mean age 41.4 years (9.6), 39% female], 170 with and 167 without diabetic nephropathy, with median follow-up of 12.3 years. Survival analyses were applied to investigate differences in plasma MMP-1, -2, -3, -9, -10, and TIMP-1-levels in patients with and without a cardiovascular event and in those who died vs survivors. All analyses were adjusted for age, sex, duration of diabetes, HbA1c, nephropathy and for other conventional cardiovascular risk factors.

RESULTS: After adjustment for potential confounders, higher MMP-2 plasma levels were significantly associated with higher incidence of cardiovascular events [HR 1.49 (95% CI 1.11; 1.99)], and higher plasma levels of MMP-1 [1.38 (1.07; 1.78)], MMP-2 [1.60 (1.19; 2.15)] and MMP-3 [1.39 (1.05; 1.85)] were associated with all-cause mortality. All associations were independent of low-grade inflammation and endothelial dysfunction as estimated by plasma markers. Associations between MMP-2 and cardiovascular events and between MMP-3 and mortality were attenuated after further adjustment for eGFR and changes in eGFR.

CONCLUSIONS: Higher levels of MMP-2 are associated with CVD and higher MMP-1, -2 and -3 with all-cause mortality. In addition, associations between MMP-2 and CVD, and MMP-3 and mortality were attenuated after adjustment for eGFR while both MMPs were associated with eGFR decline, indicating a possible mediating role of eGFR.

Original languageEnglish
Article number55
JournalCardiovascular Diabetology
Volume16
Issue number1
Number of pages12
ISSN1475-2840
DOIs
Publication statusPublished - 26 Apr 2017

    Research areas

  • Adult, Biomarkers/blood, Cardiovascular Diseases/blood, Cause of Death, Diabetes Mellitus, Type 1/blood, Female, Follow-Up Studies, Glomerular Filtration Rate, Humans, Incidence, Kidney/physiopathology, Male, Matrix Metalloproteinases, Secreted/blood, Middle Aged, Netherlands/epidemiology, Predictive Value of Tests, Prognosis, Proportional Hazards Models, Prospective Studies, Risk Assessment, Risk Factors, Time Factors, Tissue Inhibitor of Metalloproteinase-1/blood

Number of downloads are based on statistics from Google Scholar and www.ku.dk


No data available

ID: 195011551